BioGend Therapeutics Co., Ltd. (TPEX:6733)

BioGend Therapeutics Revenue

BioGend Therapeutics had revenue of 44.25M TWD in the quarter ending September 30, 2024, with 110.16% growth. This brings the company's revenue in the last twelve months to 156.64M, up 92.60% year-over-year. In the year 2023, BioGend Therapeutics had annual revenue of 109.91M with 249.51% growth.

• Revenue (ttm): 156.64M
• Revenue Growth: +92.60%
• P/S Ratio: 26.72
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 4.22B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	109.91M	78.46M	249.51%
Dec 31, 2022	31.45M	22.18M	239.26%
Dec 31, 2021	9.27M	7.88M	565.40%
Dec 31, 2020	1.39M	-68.00K	-4.65%
Dec 31, 2019	1.46M	-	-